Agree with that! Novo Nordisk did capture my attention being 2nd largest cap healthcare business globally now. Looking forward to this starting on time, so that should be within the next 3-4 weeks.
There are two past valuation points to note how silly a A$50m Market Cap is now still.
1. Sumitomo indicative A$202m cash offer 2019 2. Fujifilm US$60m (circa A$100m) deal on GvHD PRE Phase 1.
GvHD Phase 2 once complete could have a total value of around A$250m. I would expect the upfront if it repeats success like Phase1 would be around the current market cap alone.
On MSB, if they can reach A$1.4B with their pipeline currently, no approval and major past issues, then CYP looks like a relative bargain to me, and if only matches MSB today could be a 2800% return over 5-10 years.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)